On March 24, 2026 Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), reported that members of its commercial and medical affairs teams will attend the USCLC Annual Workshop 2026. The meeting, titled "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," will take place on March 26, 2026, at the Hyatt Regency Denver at Colorado Convention Center.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The United States Cutaneous Lymphoma Consortium (USCLC) Annual Workshop is widely regarded as one of the most focused scientific gatherings dedicated to cutaneous lymphomas, including cutaneous T-cell lymphoma (CTCL). The meeting brings together leading dermatologists, hematologist-oncologists, translational researchers, and academic investigators from major U.S. cancer centers who specialize in diagnosing and treating CTCL and related diseases.
This year’s workshop is expected to convene dozens of key opinion leaders and clinical investigators from leading academic institutions, with program sessions covering:
Novel molecular diagnostics and biomarkers
Radiology and digital pathology advancements
Emerging therapies for CTCL
Future clinical and research directions in cutaneous lymphoma
The workshop format emphasizes small-group discussions and direct interaction among experts, creating an environment where physicians and researchers can exchange insights about evolving treatment paradigms and clinical experience.
Citius Oncology’s team will participate in the meeting to engage with clinicians and researchers regarding the treatment landscape for CTCL and discussions regarding clinical experience with LYMPHIR (denileukin diftitox-cxdl) which Citius Oncology recently launched in the U.S.
"Our participation in the USCLC Workshop reflects our commitment to engaging directly with the leading clinicians who treat patients with cutaneous lymphoma," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. "The USCLC community represents many of the foremost experts and practitioners in CTCL care, and we look forward to productive scientific discussions regarding treatment experience, patient selection, and emerging opportunities to improve outcomes."
About the USCLC Annual Workshop
The USCLC Annual Workshop is organized by the United States Cutaneous Lymphoma Consortium, a collaborative network of leading U.S. academic centers dedicated to improving research, diagnosis, and treatment of cutaneous lymphomas. The workshop serves as a platform for leading specialists to discuss cutting-edge diagnostics, emerging therapeutics, and future research directions in CTCL and related diseases.
USCLC is the only organization in America where professionals from the collaborating disciplines of dermatology, medical oncology, radiation oncology and pathology can exchange ideas and practice tips, discuss, plan and execute scientific collaborations, develop new educational tools, and help shape the research agenda in cutaneous lymphomas. USCLC was created with the express purpose of breaking communication barriers, encouraging "outside-the-box" thinking, and fostering and supporting innovative ideas regarding the treatment and research relating to cutaneous lymphomas. The key initiatives of USCLC are a national registry, a virtual tissue repository, and a clinical trials network.
About LYMPHIR (denileukin diftitox‑cxdl)
LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.
In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.
(Press release, Citius Oncology, MAR 24, 2026, View Source [SID1234663876])